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Abstract
Single nucleotide polymorphisms (SNPs) constitute an important mode of genetic variations observed in the human
genome. A small fraction of SNPs, about four thousand out of the ten million, has been associated with genetic disorders
and complex diseases. The present study focuses on SNPs that fall on protein domains, 3D structures that facilitate
connectivity of proteins in cell signaling and metabolic pathways. We scanned the human proteome using the PROSITE web
tool and identified proteins with SNP containing domains. We showed that SNPs that fall on protein domains are highly
statistically enriched among SNPs linked to hereditary disorders and complex diseases. Proteins whose domains are
dramatically altered by the presence of an SNP are even more likely to be present among proteins linked to hereditary
disorders. Proteins with domain-altering SNPs comprise highly connected nodes in cellular pathways such as the focal
adhesion, the axon guidance pathway and the autoimmune disease pathways. Statistical enrichment of domain/motif
signatures in interacting protein pairs indicates extensive loss of connectivity of cell signaling pathways due to domain-
altering SNPs, potentially leading to hereditary disorders.
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Introduction
Hereditary disorders are often linked to rare mutations in the
form of single nucleotide polymorphisms (SNPs) [1]. Evolutionary
forces introduce many new variants into the human genome in
each generation [2]. SNPs affect the tendency to develop autism,
diabetes, and cancer and impact immune response to pathogens,
chemicals, drugs, and vaccines [3,4,5]. The HAPMAP project
presents information concerning genetic variances among ethnic
population subtypes thus implicating SNPs as key differences
across population subtypes [6].
More than ten million SNPs have been identified in the human
genome [7]. SNPs that fall into coding or promoter regions of
proteins comprise only a small fraction of the presently annotated
SNPs. To date, nearly four thousand SNPs have been mapped to
the disease/disorder status [8]. Genome wide association studies
complement clinical studies correlating SNPs to disease. However,
approaches based on statistics alone provide limited insights on
how a genetic variation causes disease.
Current methods for discovery of SNP-phenotype association
include those focusing on non-synonymous SNPs that alter
functional motifs such as binding sites [9], DNA binding motifs
[10] and sites related to protein stability and cellular processing
[11]. Computational intelligence models [12] utilize logic tree
[13,14], neural networks [15], an ensemble learning approach [15]
or evolutionary algorithms [16] to discover correlations between
SNPs and hereditary disorders and provide potential biological
insight for the observed correlation and/or causation. Overall, the
aforementioned approaches have illustrated the potential use of
computational system modeling in the discovery of links between
disease and the genotype.
This study focuses on a specific subset of human genotype-
disease association, namely the annotation of SNPs that alter
protein domains and thus potentially break bonds between
interacting proteins in cell signaling pathways [17]. Protein
domain structure is relatively flexible with respect to the amino
acid sequence defining the domain, as illustrated by the domain
annotation web tools such as Pfam [18] and PROSITE [19].
However, scanning proteins through these web tools, one can
illustrate that even a single SNP could alter the structural
configuration so extensively as to erase a domain from the
structural composition of a given protein.
In this study, we screened the human proteome for domain
annotation using the PROSITE web tool [20]. We projected
the previously annotated SNPs onto proteins and identified
those SNPs with domain altering properties. The resulting set
turned out to be highly statistically enriched among proteins
linked to genetic disorders [19]. We annotated these proteins
using a variety of bioinformatics databases and web tools and
showed that proteins with domain altering SNPs crowd the
protein networks involving focal adhesion, axon guidance,
n a t u r a lk i l l e rc e l lm e d i a t e dc ytotoxity, and neurotrophin
signaling pathways. Our predictions of linkages broken in these
pathways indicate severe reduction of connectivity in signaling
pathways associated with complex diseases and hereditary
disorders.
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Discovery of domain-altering SNPs
The human SNP database was downloaded from the NCBI
dbSNP database (build 130, released June 2009) [7]. dbSNP is an
archive containing over 10 million human SNPs, and among them,
63,899 missense SNPs. The SNPs were then projected onto
corresponding human protein sequences from the NCBI GenBank.
Peptide sequences of potentially SNP-containing proteins (in SNP-
absent and SNP-containing forms) were screened for annotation of
protein domains using PROSITE (version 20.31) [19]. A domain
with potential to contain a SNP was called D-SNPs.
The PROSITE output for each sequence was in the form of a
matrix with three columns, with the columns indicating (1) the ID
number of the PROSITE domain, (2) the binary value identifying
the presence or absence of a domain, and (3) the PROSITE
matching score (MS) if the domain was expressed as a profile
(position weight matrix) rather than expressed in the form of a
pattern (regular expression). The second and the third columns of
the output data allowed us to identify those SNPs that either
removed a domain from the protein structure or drastically altered
it when compared to sequences with and without the SNPs (DA-
SNPs). If the PROSITE domain was defined as a regular
expression, the second column was sufficient to identify whether
the domain also existed in the presence of the SNP.
For those domains expressed as a profile, we checked the third
column for the value of the matching score parameter of the same
protein with and without the SNP. We defined a domain distortion
(DD) parameter as the ratio of the difference in the matching score
(due to the presence of the SNP) to the matching score of the
sequence without the SNP. In our scans, DD varied from 0 to 0.3,
which was the maximum domain distortion observed in our
computations. Domains with DA-SNPs were defined as the sets of
domains for which the sequence with SNPs no longer fits the
regular expression, plus a set of profile domains with a finite DD
value cut off in the presence of the SNPs.
Examples of structural diagrams of proteins with DA-SNPs were
obtained using the Protein Data Bank (PDB, April 2010 version)
[21] (for the case of no SNP) and SNPs3D [22] (with SNPs, 2008
version). The structures were aligned using YASARA [23] and the
location of the SNP was marked with yellow. The lists of proteins
with D-SNPs and DA-SNPs were presented as inputs to DAVID
Bioinformatics resources [24] (version 6.7) and enriched KEGG
pathway [25] profiles and Gene Ontology [26] categories at a p-
value cut-off of 0.01.
Bonds broken between a protein with a domain altering
SNP and its neighbors in signaling pathways
We used statistical enrichment to identify protein signatures
(domains, motifs) most likely to be found among binding partners
of the proteins containing domain-altering SNPs. We created a
score matrix with rows indicating domains that can be altered by
an SNP and columns indicating domains and motifs found in
binding partners of proteins with domain altering SNPs. Each
element of the score matrix represented the number of times a
domain with an SNP was found associated with a signature
(domain, motif) on a binding partner. The web tool ELM (2010
version) [27] was used to annotate linear motifs on proteins. We
then created random protein binding partners to proteins with
SNP containing domains and created a score matrix as a
background for statistical enrichment analysis. We used the
hypergeometric test to identify those domains/motifs most likely
to signal a protein-protein interaction involving domains with DA-
SNPs. This procedure allowed us to identify signature pairs (such
as A-B) such that the presence of signature A (domain with an
SNP) in protein K and signature B in protein L would predict a
binding interaction between K and L. The link A-B is a candidate
for a bond potentially broken due to the presence of the domain
altering SNP in a cellular pathway. To eliminate possible false
positives in the estimates of bonds broken, we required the
signature pair (A-B) to be either in the DOMINE (version 2.0) [28]
database or previously annotated as a domain-motif pair as
predictive of binding interactions between two proteins [29].
Results
Our computations show that proteins with SNPs in one or more
of its domains are significantly more likely to be associated with
human disorders. Out of the 63,899 SNPs in the coding regions of
proteins, 1,782 SNPs are present in the Online Mendelian
Inheritance in Man (OMIM) database version 2009 [8]. A total
of 12,965 SNPs fall into protein domains, and 592 proteins with
domain SNPs are associated with a disease or disorder in OMIM.
The p value from hypergeometric test for the SNP enrichment
within the domain regions is zero, which indicating that SNPs in
the domain regions of proteins are highly correlated to genetic
disorders and complex diseases. This observation is consistent with
the important functions protein domains play in establishing
connectivity among proteins in cell signaling pathways [17].
Among proteins with domain SNPs, those with domain-altering
SNPs are even more likely to be associated with disorder/disease.
Domain-altering SNPs discovered in our PROSITE screening
method consists of two subsets. The first subset consists of SNPs
the sequence no longer satisfies in the regular expression for the
domain. The second subset is composed of domains defined as a
profile above a prescribed domain distortion (DD) parameter
cutoff. An example of a domain with DA-SNP is p53. Figure 1
shows the 3D structure of TP53 in the presence and absence of a
DA-SNP (SNP rs28934571), as well as the poor alignment of these
structures due to the presence of the SNP. This SNP occurs at
sequence position 249 and causes losses of hydrogen bonds and
salt bridge bonds. The root mean square deviation (RMSD) [30]
between TP53 and its DA-SNP structure is 52.6496 A. Another
example of a domain-altering SNP is SNP rs29001653. This SNP
alters the visual pigments retinal binding site of the protein coded
by the RHO gene, resulting in night blindness. The altered
structure is over packed in the 3D space and the RMSD is 2.9835
A. Because 3D domain structure is not available for most domains
with synonymous SNPs at present time, it is not possible to define
domain-altering SNP based on the RMSD evaluations, and hence
the use of domain-altering SNP definition described in the
methods section.
We evaluated the statistical enrichment of the domain altering
SNPs in the OMIM Database as a function of the DD cutoff, as
shown in Table 1. In all cases, the p value ,0.05 indicates
significance of enrichment with respect to all domains with SNPs.
The list of proteins with domain-altering SNPs in which both the
protein and the SNP were linked to the same disease/disorder is
presented in Table S1 for DD .0.10. The phenotypes were
identified by reading through the OMIM disease/disorder
documentations. The table covers proteins associated with a
variety of diseases ranging from pancreatic cancer, epilepsy, and to
carpal tunnel syndrome. Beside the OMIM evaluations, SNPs
reported in various cancer lines were tested [31] for their position
relative to domains and domain altering potential. Out of 13
unique SNP IDs presented in Table 2 of Zhang [31], one was
found in the PROSITE domain region, and it corresponded to a
domain-altering SNP associated with pancreas cancer.
Domain SNPs and Disease
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function categories involving calcium ion binding, adenyl
ribonucleotide binding, protein kinase activity, and endopeptidase
activity at DD .0.10. The DD cutoff of 0.10 corresponds to 598
domain-altering SNPs present in 505 proteins. Among these
proteins, 242 had at least one known binding partner in the
Human Protein Reference Database (HPRD) [32]. The GO level
5 molecular function gene ontology categories shown in Figure 2A
are statistically enriched with proteins with domain altering SNPs
(p,0.01). The list of GO categories shown in the figure indicates
that proteins with domain-altering SNPs comprise key nodes in
protein networks; their loss of connectivity would likely have a
significant effect on cellular signal transduction.
Shown in Figure 2B is the list of KEGG pathways statistically
enriched (p,0.01) in proteins with domain-altering SNPs at DD
.0.10. The list contains pathways closely associated with cancer,
neurological, and immunological diseases. Proteins with domain
altering SNPs are marked in the pathways for focal adhesion and
natural killer cell mediated cytotoxicity in Figure 3. Nodes colored
in pink in these figures indicate proteins with domain-altering
SNPs, while those in blue are their immediate binding partners as
identified in HPRD. The purple nodes are proteins that belong to
both the pink and blue groups. The pathway diagrams shown in
Figure 3 illustrate the presence of proteins with domain altering
SNPs from the very beginning of the pathway at the cell
Figure 1. Alteration of 3D structure of TP53 due to presence of SNP rs28934571. The TP53 protein wild type (light blue) and the same
protein with the SNP (pink) are shown on the left, and their optimal alignment on the right. The SNP position is colored as yellow in resulting
structure.
doi:10.1371/journal.pone.0012890.g001
Table 1. Statistical enrichment of domain altering SNPs in the
OMIM database.
# D-SNP
# D-SNP &
OMIM DD cut-off # SNPs
OMIM
match p value
12965 801 0.05 1152 75 0.0444
0.1 598 46 0.0197
0.15 497 40 0.016
0.2 451 35 0.028
Each row gives the overall statistics of domain-altering SNPs and the p value for
statistical enrichment in OMIM at a given domain distortion (DD) parameter
cutoff. The p values are computed based on hypergeometric test.
doi:10.1371/journal.pone.0012890.t001
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important cellular processes.
Next, we estimated the links broken in these pathways due to
domain-altering SNPs. We have determined domain-domain and
domain-motif pairs (signature pairs) statistically enhanced inprotein-
protein interactions involving proteins with domain-altering SNPs.
The results show that only a very small fraction of possible signature
pairs are statistically enriched in PPIs presented in HPRD [26].
Table 2. The top ten most highly connected proteins with domain altering SNPs (DD.0.10).
Gene Protein Name # broken # intact
ADRBK1 beta-adrenergic receptor kinase 1 29 9
SH2D1A SH2 domain-containing protein 1A 12 0
TCF3 transcription factor E2-alpha 19 25
APBA2 amyloid beta A4 precursor protein-binding family A 8 1
NCK1 cytoplasmic protein NCK1 61 3
PRKCH protein kinase C 80
YWHAE 14-3-3 protein epsilon 46 21
TOPBP1 topoisomerase (DNA) II binding protein 1 11 3
BCAR1 breast cancer anti-estrogen resistance protein 1 45 3
RIMS1 regulating synaptic membrane exocytosis protein 1 11 3
doi:10.1371/journal.pone.0012890.t002
Figure 2. Statistically enriched Gene Ontology (GO) molecular function level 5 (MF) categories (2A) and KEGG cellular pathways
(2B) for DD .0.10 at p value ,0.01.
doi:10.1371/journal.pone.0012890.g002
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12890We used statistically enriched signature pairs in the estimates of
links broken due to a protein expressing a domain-altering SNP. A
link (transient or stable) between two proteins is assumed broken
due to a domain altering SNP if the opposing protein pair contains
at least one signature enriched with the SNP containing domain in
the PPIs in HPRD. Shown in Figure 4 is the histogram for proteins
with DA-SNPs, thus indicating the number of edges such proteins
have in the absence of an SNP and the number of edges estimated
to be broken due to the presence of the SNP. The figure indicates
potentially extensive loss of connectivity of proteins with DA-SNPs
to neighboring proteins in protein networks.
The protein links we estimate to be broken between a protein
containing a DA-SNP and its immediate neighbors are shown in
Figure 3A and 3B for focal adhesion and natural killer cell
mediated immunity. The links deemed to be broken using the
statistical enrichment method described above are shown as
marked with a circle containing either a red or green ‘‘x’’ or a red
‘‘+’’ sign. The links with red ‘‘x’’ correspond to the domain
signature pairs present in the DOMINE database described as
predicting PPIs with high accuracy [27]. The links with a green
‘‘x’’ correspond to domain-motif associations deemed highly
predictive of PPIs [25]. The links marked (+) are links estimated
to be broken by statistical enrichment of the domain pairs only.
Note that, even when we exclude these latter links, the pathway
connectivity (number of edges per node) is strongly influenced
when an SNP drastically alters the 3D shape of a domain
responsible for connections to upstream and downstream partners.
This assertion is further enhanced by the list of highly connected
proteins with domain altering SNPs given in Table 2. For
example, the transcription factor TCF3 has 44 known binding
partners, and links to 19 of these partners could be broken due to
the presence of the domain-altering SNP. Taken together, our
study exposes the importance of domain SNPs in the progression
of some of the most prominent complex and/or hereditary
diseases.
Discussion
The genome wide association studies seeking a correlation
between genetic makeup and complex diseases, such as cardio-
vascular diseases [33], autism [34], and diabetes [35]. Results
implicate a handful of SNPs correlated with these complex disease
states. Correlation is based on purely statistical methods, and in
many cases, SNPs found to be significantly associated with a
disease fell into the non-coding regions of DNA distant from a
protein coding gene [12]. As the population subsets for genome-
wide studies grow in size with increasing research efforts and time,
and as these sets are better controlled for demographic and
environmental variables, one would expect the discovery of sets of
additional SNPs strongly correlated with hereditary disorders and
disease subtypes. Nevertheless, a system bioinformatics approach is
needed to explore how a disease-correlated SNP alters cell
signaling and metabolic pathways, thus contributing to the
initiation of a disorder or a disease.
This study explores the mechanisms by which SNPs that fall
into protein domains in the human genome potentially contribute
to disease. Protein domains are functional units closely aligned
with post-transcriptional modification (as in phosphorylation) and
play important roles in establishing the connectivity of cell
signaling networks via binding to upstream and downstream
proteins [4,36]. Our computations indicate that the p value for
disease association of SNPs that fall into protein domains and
occur by random chance is practically zero. Within this group of
SNPs, those with domain-altering properties are even more likely
to be associated with a disease state. We have defined a domain-
altering SNP as one that either alters the sequence such that it no
longer satisfies the regular expression of the domain or that the
domain is extensively deformed as quantified by the domain
distortion index. Proteins with domain-altering SNPs crowd
cellular pathways involved in neurological, and immunological
diseases, as well as in cancers such as the pancreatic cancer.
How does an SNP with domain altering properties affect the
connectivity of pathways? The key to answering this question lies
in the discovery of the set of proteins that bind to proteins under
consideration via the domain containing the SNP. The grammar
of protein-protein interactions in terms of primary sequence and/
or 3D structure is yet to be fully understood. We used a statistical
enrichment approach to identify protein domains (motifs) on the
opposing protein most frequently associated with the SNP-
containing domain under consideration. We then assumed a
bond (transient or steady) was broken whenever we came across
such a signature pair among the immediate partners of the protein
with a domain altering SNP. Results shown in the present study
for focal adhesion and the natural killer cell mediated cytotoxicity
pathways indicate extensive loss of connectivity in these cellular
pathways, caused by the presence of domain altering SNPs among
the proteins in these pathways. Even when we reduced the
estimates of bonds broken with the use of signature pairs already
known to predict protein-protein interactions, the loss of
connectivity persisted at multiple cell compartments. We obtained
qualitatively similar results for axon guidance and neutrophin
signaling pathways altered by the presence of a domain altering
SNP (not shown).
In conclusion, proteins with domain-altering SNPs are statisti-
cally enriched in the list of proteins known to be associated with
Figure 4. Figure 4 shows a histogram for proteins containing a
domain-altering SNP indicating the number of edges each has
in the absence of SNP, and the estimate of broken edges in the
presence of the SNP.
doi:10.1371/journal.pone.0012890.g004
Figure 3. Proteins with domain altering SNPs on KEGG pathways for focal adhesion (3A) and natural killer cell mediated
cytotoxicity (3B). Also shown these diagrams are the broken edges (links) estimated by statistical enrichment of domain pairs in protein-protein
interactions (circles containing + or x signs.
doi:10.1371/journal.pone.0012890.g003
Domain SNPs and Disease
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logical, neurological and cardiomyopathy disorders. Protein
functional groups statistically enriched with proteins with domain
altering SNPs include calcium ion binding, adenyl ribonucleotide
binding, protein kinase activity, endopeptidase activity, serine-type
peptidase activity, DNA binding, and GTPase binding proteins.
Supporting Information
Table S1 List of proteins with domain altering SNPs (DD .0.1)
for which both the SNP and the protein were previously associated
in the literature with a hereditary disorder or complex disease. The
columns in the table present the gene symbol, the SNP ID, the
name of the domain with the SNP, whether is DD violation (yes)
or violation of regular expression (no), and the associated disorder/
disease.
Found at: doi:10.1371/journal.pone.0012890.s001 (0.02 MB
XLS)
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